Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach and integrating a biomarker strategy to develop targeted drugs to treat leukemias, lymphomas and solid tumor cancers. Our drug candidate, onvansertib, is a first-in-class, 3rd generation Polo-like Kinase Inhibitor with best-in-class attributes. Onvansertib is highly-selective for PLK1, which is over-expressed in most cancers; it is orally administered; synergistic in combination with numerous chemotherapies and targeted therapeutics; has a half-life of 24-hours which allows for flexibility in dosing and schedule. We are developing onvansertib as part of combination regimens with already approved drugs for the treatment of cancers and indications where there is a significant medical need for new treatment options.

Video Overview
Trovagene Oncology Company Overview - April 2019
Recent News
Apr 23, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of...

Apr 5, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of...

Apr 5, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of...

More >

Stock Information
NASDAQTROV
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@trovagene.com

Contact

Events
April 1, 2019 - April 2, 2019

Dr. Thomas Adams, CEO and Chairman, and Dr. Mark Erlander, CSO, will be presenting and conducting one-on-one meetings with investors at the Spring Investor Summit on April 1-2 at the Essex House...

January 29, 2019 - March 29, 2019

Dr. Thomas Adams, CEO and Chairman, and Dr. Mark Erlander, CSO, will present an overview of Trovagene Oncology and provide an update on the clinical development program with Onvansertib....

October 24, 2018
8:30am - 9:30am EDT

Trovagene management team will provide an update on the Company's clinical development program and associated financing, key milestones, and collaboration and partnering activities. The Webcast...